Joshua Reuss, MD
Medical Oncology · Washington, DCNPI 1740609825
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (45.8%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Genentech, Inc. at 46.4% of the total. Reporting peaked in 2022 at $113,528 and has fallen 66.5% since, to $37,992 in 2025. Among medical oncology clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 142 payments — averaging $1536.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$101K
- AstraZeneca$41K
- Merck$10K
- Daiichi Sankyo Inc.$8K
- Gilead$5K
- Lilly USA, LLC$5K
- plus $47K from 21 others
Across 13 payments — averaging $27,731 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$182K
- Amgen$69K
- Genentech, Inc.$56K
- AstraZeneca$38K
- Verastem, Inc.$10K
- Exelixis Inc.$5K
What the payments were for
- Consulting fees$90,70142%
- Speaking & faculty fees$17,7788%
- Grants$100,00046%
- Travel & lodging$6,0603%
- Food & beverage$3,6732%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 2 | $101,280 |
| AstraZeneca | 44 | $41,204 |
| Merck | 6 | $9,796 |
| Daiichi Sankyo Inc. | 10 | $8,160 |
| Gilead | 3 | $5,442 |
| Lilly USA, LLC | 2 | $5,200 |
| AbbVie | 8 | $4,755 |
| Novocure Inc. | 12 | $4,500 |
| Sanofi | 1 | $4,216 |
| Ventana Medical Systems, Inc. | 2 | $3,640 |
| Janssen Scientific Affairs, LLC | 2 | $3,590 |
| Regeneron | 9 | $3,421 |
| E.r. Squibb & Sons, L.L.C. | 4 | $3,277 |
| Boehringer Ingelheim International GmbH | 1 | $3,045 |
| EMD Serono, Inc. | 2 | $2,975 |
| Pfizer | 3 | $2,685 |
| Johnson & Johnson | 4 | $2,234 |
| Regeneron Healthcare Solutions, Inc. | 5 | $2,148 |
| Daiichi Sankyo Europe GmbH | 1 | $1,875 |
| Astrazeneca UK Limited | 3 | $1,669 |
| Array Biopharma Inc | 3 | $1,544 |
| Seagen Inc. | 2 | $525 |
| Jazz Pharmaceuticals Inc. | 4 | $413 |
| Genentech USA, Inc. | 6 | $411 |
| Amgen | 1 | $95 |
| Karyopharm Therapeutics Inc. | 1 | $87 |
| Caris MPI, Inc. | 1 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$218,229 in reported general payments places this provider in the 95th percentile of 29 medical oncology providers in District of Columbia.
See all medical oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 67 | $1,107,094 |
| RetevmoSelpercatinib | 13 | $299,640 |
| Erlotinib Hcl | 12 | $989 |
| Levothyroxine Sodium | 15 | $596 |
| Oxycodone Hcl | 30 | $512 |
| Ondansetron Hcl | 16 | $201 |
| Mirtazapine | 14 | $119 |
| Prednisone | 19 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $41,204 | $1,107,09467 claims |
| Lilly USA, LLCRetevmo | $5,200 | $299,64013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 29 medical oncology providers in District of Columbia.
Other medical oncology in Washington
- Nancy DawsonWashington$1.7M
- Pashna MunshiWashington$189K
- Michael PishvaianWashington$147K
- Kieron DunleavyWashington$139K
- Asim AminWashington$120K
- Mitchell SmithWashington$41K
- Channing PallerWashington$33K
- Solmaz SahebjamWashington$31K
- Khaled El-ShamiWashington$27K
- Kimberley DoucetteWashington$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.